Qiagen, Verogen to offer forensic testing kits, services

By LabPulse.com staff writers

June 30, 2021 -- Qiagen and Verogen have teamed up to offer labs tools and support for human identification workflows in forensic testing based on next-generation sequencing (NGS).

Under the deal, Qiagen will offer Verogen's human identification sequencing and analysis products that run on MiSeq FGx sequencers from Illumina. Qiagen also can distribute the company's portfolio, including kits based on Verogen's ForenSeq assay, MiSeq FGx sequencing system, and the Universal Analysis software.

The deal also includes an expansion of their partnership through future ForenSeq-based assays.

Furthermore, the companies will collaborate to commercialize a menu of forensically validated workflows for NGS that combine Verogen's library-prep products with Qiagen's QIAseq products and tools.

The financial terms of the deal have not been disclosed.

FDA expands use of Qiagen lung cancer mutation test
The U.S. Food and Drug Administration (FDA) approved the expanded use of a Qiagen diagnostic kit as a companion test for the identification of non-small...
Qiagen inks deal with Mirati on cancer companion diagnostic
Qiagen has announced a global collaboration with Mirati Therapeutics to continue developing a tissue-based, KRAS companion diagnostic to identify patients...
Qiagen posts strong sales, earnings growth in Q1
Strong growth in both COVID-19 and non-COVID-19 product groups propelled Qiagen to a 48% increase in net sales at constant exchange rates in its first...
Qiagen, DiaSorin debut Lyme disease assay
Qiagen and DiaSorin announced the launch of the Liaison LymeDetect assay for early detection of the Lyme Borreliosis infection. The test detects immunoglobulin...
Qiagen secures EUA for COVID-19 test
Qiagen has received emergency use authorization (EUA) from the U.S. Food and Drug Administration for NeuMoDx, a test that helps clinicians distinguish...

Copyright © 2021 LabPulse.com

Last Updated np 9/1/2021 12:24:52 PM